Purpose: Recent evidences suggest that, despite the large use of levothyroxine (L-T4), up to 40% of patients are over-treated developing sub-clinical hyperthyroidism. We compared TSH, fT4 and fT3 serum levels of elderly patients in treatment with liquid and tablet L-T4 formulations over a period of time of five years. Subjects: Patients were recruited by searching the database of those treated and followed at the Thyroid Unit of the University of Brescia. Results: 299 patients (251 female, 48 male) were treated with L-T4 in tablet form (Group T) and 118 subjects (107 female, 11 male) with liquid LT4 (Group L). The two groups were superimposable by age, median L-T4 dosage, TSH, fT4 and fT3 values. A slightly but not significantly higher BMI value was observed among patients of Group L over those of Group T (26.9±2.9 vs. 26.4±2.1, Kg/cm 2 , respectively). During five years of LT-4 treatment, sub-clinical or overhypothyroidism was found in 13 (4.3%) and 3 (2.5%) patients of Group T and Group L (p=0.335), whereas, subclinical or clinical hyperthyroidism was significantly more frequent among patients of Group T than those of Group L [69 (23%) vs. 5 (4.2%) patients, (p=0.0001)]. Logistic regression analysis showed that only the Tablets were associated with the risk of developing subclinical or hyperthyroidism [OR 2•354 (1•136-4•827), p=0.021]. Conclusions: We show a greater stability in the thyroid profile of hypothyroid elderly patients in treatment with liquid thyroxine as opposed to those being treated by tablet formulation over 5 years of follow-up.